<DOC>
	<DOCNO>NCT00364273</DOCNO>
	<brief_summary>GSK159802 potent , inhale , long act selective beta-2-receptor agonist ( LABA ) , develop daily treatment asthma COPD part combination product daily inhale corticosteroid also standalone product treatment COPD . Stimulation beta-2-agonist lung mainly relax bronchial smooth muscle cell result bronchodilation . Unwanted systemic side effect related beta-2-agonist treatment tachycardia , tremor , hyperglycemia hypokalemia limit local administration also tend show tachyphylaxis . The LABAs currently available ( e.g. , salmeterol , formoterol ) require twice-daily administration , give duration action . Therefore , significant opportunity once-daily inhaled medication improve patient compliance overall disease management providing sustain , 24-hour bronchodilation .</brief_summary>
	<brief_title>GSK159802 In Healthy Male Subjects And Asthmatics</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Inclusion criterion : Body mass index within range 18.529.9 ( kg/m2 ) Current nonsmoker use tobacco product 6month period precede screen visit pack history &lt; 10 pack year . Additional criterion Cohorts 2 3 ( Asthmatic Patients ) : Subjects document history mild moderate asthma , exclusion significant pulmonary disease Subjects clinically stable asthma within 4 week precede screen visit screen prebronchodilator FEV1 great 60 % le 90 % predict . During screen visit , subject must demonstrate presence reversible airway disease , define increase FEV1 &gt; equal 12.0 % baseline absolute change &gt; equal 300 mL within 30 minute follow 400 mcg salbutamol . Exclusion criterion : Any clinically relevant abnormality Subjects screen haemoglobin value &lt; 11 g/dL The subject participate clinical study New Chemical Entity ( NCE ) within past 112 day clinical study drug previous 84 day Subjects know hypersensitivity salmeterol salbutamol ingredient preparation .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Asthma</keyword>
</DOC>